Skip to main content
. 2022 May 6;33(5):969–981. doi: 10.1021/acs.bioconjchem.2c00167

Figure 5.

Figure 5

Blocking assay with HER2+ BT474 cells. Schematic of the study: (A) targeted MaMAs conjugated with fluorescently labeled trastuzumab antibodies (A647-aHER2-MaMAs) binding to HER2 positive cells; (B) blocking assay in which HER2 receptors are blocked by preincubation with free trastuzumab that precludes subsequent binding of A647-aHER2-MaMAs. (C) Optical microscopy images of (from left to right) BT474 cells alone (untreated control); BT474 A647-aHER2-MaMAs (BT474 cells labeled with A647-aHER2-MaMAs); and BT474 blocking assay where BT474 cells were preincubated with free trastuzumab antibodies before labeling with A467-aHER2-MaMAs. The images were acquired using a Zeiss Axio Observer.Z1m microscope equipped with a Hamamatsu ORCA-ER camera (Bridgewater, NJ) under a 40× objective lens. Fluorescence images were obtained with BP 640/30 nm excitation and BP 690/50 nm emission bandpass filters. Scale bar is 40 μm.